Canadian Cancer Trials Group Bulletins

Trial Management Group

Canadian Cancer Trials Group SC.23 Accrues 100th Patient

Canadian Cancer Trials Group is very pleased to announce that SC.23 (A Randomized Phase III Double Blind Study of Dexamethasone versus Placebo in the Prophylaxis of Radiation-Induced Pain Flare following Palliative Radiotherapy for Bone Metastases) had its 100th patient randomized on July 19, 2012!

The trial is now over one-third of the way to reaching its target accrual of 298 patients.

SC.23 is being conducted only at centres in Canada.

The Canadian Cancer Trials Group would like to thank all participating centres across the country for their continued support. Congratulations to everyone who has contributed to the ongoing success of this trial!
Keep up the good work!

If you have any questions about this trial, please contact Carolyn Wilson, SC.23 Study Coordinator, at 613-533-6430 or